Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of cancer neoepitopes needs new rules.

Seminars in immunology - 1 Feb 2020

Brennick Cory A, George Mariam M, Srivastava Pramod K, Karandikar Sukrut H

Abstract excerpt

Tumors are immunogenic and the non-synonymous point mutations harbored by tumors are a source of their immunogenicity. Immunologists have long been enamored by the idea of synthetic peptides corresponding to mutated epitopes (neoepitopes) as specific "vaccines" against tumors presenting those neoepitopes in context of MHC I. Tumors may harbor hundreds of point mutations and it would require effective prediction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Biomarkers, Tumor
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitope Mapping

Share to Epitopes

Share to Histocompatibility Antigens Class I

Share to Immunomodulation

Share to T-Lymphocyte Subsets

Source

Identifiers

PMID: 31952902
DOI: 10.1016/j.smim.2020.101387

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of cancer neoepitopes needs new rules.PMID 31952902Read ↗

Predicting T cell recognition of MHC class I restricted neoepitopesSemantic proximity Read ↗

An unbiased approach to defining bona fide cancer neoepitopes that elicit immune-mediated cancer rejectionSemantic proximity Read ↗

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity.Semantic proximity Read ↗

Structural and physical features that distinguish tumor-controlling from inactive cancer neoepitopesSemantic proximity Read ↗

Computational Prediction and Validation of Tumor-Associated Neoantigens.Semantic proximity Read ↗

Pan-cancer analysis of neoepitopesSemantic proximity Read ↗

Mutation position is an important determinant for predicting cancer neoantigens.Semantic proximity Read ↗

Role of in silico structural modeling in predicting immunogenic neoepitopes for cancer vaccine development.Semantic proximity Read ↗

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapySemantic proximity Read ↗

Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.Semantic proximity Read ↗

Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?Semantic proximity Read ↗

MHC-I binding affinity derived metrics fail to predict tumor specific neoantigen immunogenicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.